CS263952B1 - Remedy with antiviral effect - Google Patents

Remedy with antiviral effect Download PDF

Info

Publication number
CS263952B1
CS263952B1 CS853018A CS301885A CS263952B1 CS 263952 B1 CS263952 B1 CS 263952B1 CS 853018 A CS853018 A CS 853018A CS 301885 A CS301885 A CS 301885A CS 263952 B1 CS263952 B1 CS 263952B1
Authority
CS
Czechoslovakia
Prior art keywords
formula
compounds
virus
cells
effect
Prior art date
Application number
CS853018A
Other languages
Czech (cs)
English (en)
Inventor
Antonin Rndr Drsc Holy
Ivan Ing Rosenberg
Original Assignee
Holy Antonin
Rosenberg Ivan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Holy Antonin, Rosenberg Ivan filed Critical Holy Antonin
Priority to CS853018A priority Critical patent/CS263952B1/cs
Priority to IL78553A priority patent/IL78553A/xx
Priority to US06/854,087 priority patent/US4724233A/en
Priority to AU56468/86A priority patent/AU586860B2/en
Priority to DK184186A priority patent/DK167342B1/da
Priority to CA000507510A priority patent/CA1272956A/en
Priority to EG241/86A priority patent/EG18436A/xx
Priority to GR861089A priority patent/GR861089B/el
Priority to PT82457A priority patent/PT82457B/pt
Priority to PH33699A priority patent/PH23112A/en
Priority to NZ215939A priority patent/NZ215939A/xx
Priority to AT86105776T priority patent/ATE73663T1/de
Priority to EP86105776A priority patent/EP0205826B1/de
Priority to JP61097811A priority patent/JPH0692307B2/ja
Priority to DE8686105776T priority patent/DE3684363D1/de
Priority to ZA863133A priority patent/ZA863133B/xx
Publication of CS263952B1 publication Critical patent/CS263952B1/cs
Priority to HK217296A priority patent/HK217296A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CS853018A 1985-04-25 1985-04-25 Remedy with antiviral effect CS263952B1 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
CS853018A CS263952B1 (en) 1985-04-25 1985-04-25 Remedy with antiviral effect
IL78553A IL78553A (en) 1985-04-25 1986-04-21 Therapeutic compositions of phosphonylmethoxyalkyl adenines
US06/854,087 US4724233A (en) 1985-04-25 1986-04-21 Therapeutical application of phosphonylmethoxyalkyl adenines
AU56468/86A AU586860B2 (en) 1985-04-25 1986-04-22 Therapeutical application of phosphonylmethoxyalkyl adenines
DK184186A DK167342B1 (da) 1985-04-25 1986-04-22 Terapeutisk praeparat til behandling af virussygdomme samt anvendelse af et 9-(fosfonylmetoxyalkyl)adeninderivat til fremstilling af praeparatet
GR861089A GR861089B (en) 1985-04-25 1986-04-24 Therapeutic application of phosponylmethoxy alkyl ademines
EG241/86A EG18436A (en) 1985-04-25 1986-04-24 Therapeutical application of phosponylmethoxy-alkyl adenines
CA000507510A CA1272956A (en) 1985-04-25 1986-04-24 Therapeutical application of phosphonylmethoxy-alkyl adenines
PT82457A PT82457B (pt) 1985-04-25 1986-04-24 Processo de preparacao de uma composicao farmaceutica com base em fosfonil-metoxi-alquil-adeninas com actividade antiviral
PH33699A PH23112A (en) 1985-04-25 1986-04-24 Therapeutical application of phosphonylmethoxyalkyl adenines
NZ215939A NZ215939A (en) 1985-04-25 1986-04-24 Phosphonyl methoxyadenine antiviral compositions
AT86105776T ATE73663T1 (de) 1985-04-25 1986-04-25 Phosphonylmethoxyalkyl-adeninen zur behandlung von viruskrankheiten.
EP86105776A EP0205826B1 (de) 1985-04-25 1986-04-25 Phosphonylmethoxyalkyl-Adeninen zur Behandlung von Viruskrankheiten
JP61097811A JPH0692307B2 (ja) 1985-04-25 1986-04-25 アデニン誘導体の治療的適用
DE8686105776T DE3684363D1 (de) 1985-04-25 1986-04-25 Phosphonylmethoxyalkyl-adeninen zur behandlung von viruskrankheiten.
ZA863133A ZA863133B (en) 1985-04-25 1986-04-25 Therapeutical application of phosphonylmethoxyalkyl adenines
HK217296A HK217296A (en) 1985-04-25 1996-12-19 Phosphonylmethoxy alkyl adenines for the treatment of virus diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CS853018A CS263952B1 (en) 1985-04-25 1985-04-25 Remedy with antiviral effect

Publications (1)

Publication Number Publication Date
CS263952B1 true CS263952B1 (en) 1989-05-12

Family

ID=5369042

Family Applications (1)

Application Number Title Priority Date Filing Date
CS853018A CS263952B1 (en) 1985-04-25 1985-04-25 Remedy with antiviral effect

Country Status (17)

Country Link
US (1) US4724233A (de)
EP (1) EP0205826B1 (de)
JP (1) JPH0692307B2 (de)
AT (1) ATE73663T1 (de)
AU (1) AU586860B2 (de)
CA (1) CA1272956A (de)
CS (1) CS263952B1 (de)
DE (1) DE3684363D1 (de)
DK (1) DK167342B1 (de)
EG (1) EG18436A (de)
GR (1) GR861089B (de)
HK (1) HK217296A (de)
IL (1) IL78553A (de)
NZ (1) NZ215939A (de)
PH (1) PH23112A (de)
PT (1) PT82457B (de)
ZA (1) ZA863133B (de)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5047533A (en) * 1983-05-24 1991-09-10 Sri International Acyclic purine phosphonate nucleotide analogs
CS264222B1 (en) * 1986-07-18 1989-06-13 Holy Antonin N-phosphonylmethoxyalkylderivatives of bases of pytimidine and purine and method of use them
US5650510A (en) * 1986-11-18 1997-07-22 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Antiviral phosphonomethoxyalkylene purine and pyrimidine derivatives
AU613592B2 (en) * 1986-11-18 1991-08-08 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Antiviral phosophonomethoxy-alkyene purine and pyrimide derivatives
US5284837A (en) * 1988-05-06 1994-02-08 Medivir Ab Derivatives of purine, process for their preparation and a pharmaceutical preparation
EP0353955A3 (de) * 1988-08-02 1991-08-14 Beecham Group Plc Chemische Verbindungen
US5688778A (en) * 1989-05-15 1997-11-18 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Nucleoside analogs
US5302585A (en) * 1990-04-20 1994-04-12 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Use of chiral 2-(phosphonomethoxy)propyl guanines as antiviral agents
DK0481214T3 (da) * 1990-09-14 1999-02-22 Acad Of Science Czech Republic Prolægemidler af phosphonater
CZ287745B6 (cs) * 1991-10-11 2001-01-17 Ústav organické chemie a biochemie AV ČR Acyklické fosfonomethoxyalkylsubstituované alkenylové a alkinylové deriváty purinu a pyrimidinu
US6057305A (en) * 1992-08-05 2000-05-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Antiretroviral enantiomeric nucleotide analogs
US5514798A (en) * 1993-06-02 1996-05-07 Gilead Sciences, Inc. Method and cyclic carbonates for nucleotide analogues
CA2171868A1 (en) * 1993-09-17 1995-03-23 Petr Alexander Method for dosing therapeutic compounds
US5798340A (en) * 1993-09-17 1998-08-25 Gilead Sciences, Inc. Nucleotide analogs
NZ283658A (en) * 1994-04-04 1999-09-29 William R Freeman Compositions and treatment of increased intraocular pressure with phosphonyl-alkyloxy-pyrimidines/purines (nucleosides)
US5468752A (en) * 1994-04-04 1995-11-21 Freeman; William R. Treatment of conditions of abnormally increased intraocular pressure by administration of HPMPC and related phosphonylmethoxyalkylcytosines
US5977061A (en) * 1995-04-21 1999-11-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic N6 - substituted nucleotide analagues and their use
US6093816A (en) 1996-06-27 2000-07-25 Isis Pharmaceuticals, Inc. Cationic lipids
US6635278B1 (en) 1998-12-15 2003-10-21 Gilead Sciences, Inc. Pharmaceutical formulations
TWI230618B (en) * 1998-12-15 2005-04-11 Gilead Sciences Inc Pharmaceutical compositions of 9-[2-[[bis[(pivaloyloxy)methyl]phosphono]methoxy]ethyl]adenine and tablets or capsules containing the same
US7205404B1 (en) * 1999-03-05 2007-04-17 Metabasis Therapeutics, Inc. Phosphorus-containing prodrugs
EP1244668B1 (de) * 2000-01-07 2006-04-05 Universitaire Instelling Antwerpen Purin derivate, ihre herstellung und verwendung
JP4651264B2 (ja) 2000-07-21 2011-03-16 ギリアード サイエンシーズ， インコーポレイテッド ホスホネートヌクレオチドアナログのプロドラッグならびにこれを選択および作製するための方法。
TR200302288T2 (tr) 2001-06-29 2004-12-21 Institute Of Organic Chemistry And Biochemistry Academy Of Terapi için yeni bileşikler ve metotlar.
EP1504014B1 (de) * 2002-05-13 2015-12-02 Metabasis Therapeutics, Inc. Verfahren zur herstellung zyklischer prodrugs von pmea und pmpa
JP4476811B2 (ja) * 2002-05-13 2010-06-09 メタバシス・セラピューティクス・インコーポレイテッド Ｐｍｅａおよびそのアナログの新規ホスホン酸系プロドラッグ
AU2003284800A1 (en) * 2002-11-12 2004-06-03 Tianjin Kinsly Pharmaceutical Co., Ltd. A new crystal form of adefovir dipivoxil and its composition
US20040224917A1 (en) 2003-01-14 2004-11-11 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
ATE496056T1 (de) 2003-06-16 2011-02-15 Acad Of Science Czech Republic Pyrimidinverbindungen mit phosphonatgruppen als antivirale nucleotidanaloga
KR20070029196A (ko) * 2004-06-08 2007-03-13 메타베이시스 테라퓨틱스, 인크. 고리 에스테르의 루이스 산 매개 합성
CN100338080C (zh) * 2004-06-16 2007-09-19 山东中科泰斗化学有限公司 9－[2－(膦羧基甲氧基)乙基]腺嘌呤双环醇酯及其制备方法
ES2720618T3 (es) 2004-07-27 2019-07-23 Gilead Sciences Inc Análogos de fosfonato de compuestos de inhibidores de VIH
EP1831235B1 (de) 2004-12-16 2013-02-20 The Regents of The University of California Arzneimittel für die lungen
WO2006130217A2 (en) * 2005-04-01 2006-12-07 The Regents Of The University Of California Substituted phosphate esters of nucleoside phosphonates
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
FR2908133B1 (fr) * 2006-11-08 2012-12-14 Centre Nat Rech Scient Nouveaux analogues de nucleotides comme molecules precurseurs d'antiviraux
PT2514750E (pt) 2007-06-18 2014-01-23 Sunshine Lake Pharma Co Ltd Tiazolil dihidropirimidinas substituídas com bromo-fenilo
TWI444384B (zh) 2008-02-20 2014-07-11 Gilead Sciences Inc 核苷酸類似物及其在治療惡性腫瘤上的用途
US7935817B2 (en) * 2008-03-31 2011-05-03 Apotex Pharmachem Inc. Salt form and cocrystals of adefovir dipivoxil and processes for preparation thereof
AU2009333559B2 (en) 2008-12-09 2015-03-12 Gilead Sciences, Inc. Modulators of toll-like receptors
EP2411392B1 (de) 2009-03-26 2014-02-26 Daewoong Pharmaceutical Co., Ltd. Neue kristallformen von adefovirdipivoxil und verfahren zu deren herstellung
US20110223131A1 (en) 2010-02-24 2011-09-15 Gilead Sciences, Inc. Antiviral compounds
NZ611438A (en) 2010-12-10 2015-06-26 Sigmapharm Lab Llc Highly stable compositions of orally active nucleotide analogues or orally active nucleotide analogue prodrugs
RS57796B1 (sr) 2013-03-15 2018-12-31 Univ California Diestri acikličnog nukleozid fosfonata
WO2015038421A1 (en) 2013-09-10 2015-03-19 Dow Corning Corporation Wear-resistant silicon eutectic alloy components and methods of making the same
US10449210B2 (en) 2014-02-13 2019-10-22 Ligand Pharmaceuticals Inc. Prodrug compounds and their uses
WO2015195538A1 (en) 2014-06-17 2015-12-23 Dow Corning Corporation Decorative shape-cast articles made from silicon eutectic alloys, and methods for producing the same
CN106687118A (zh) 2014-07-02 2017-05-17 配体药物公司 前药化合物及其用途
WO2016001907A1 (en) 2014-07-02 2016-01-07 Prendergast Patrick T Mogroside iv and mogroside v as agonist/stimulator/un-blocking agent for toll-like receptor 4 and adjuvant for use in human/animal vaccine and to stimulate immunity against disease agents.
TWI733652B (zh) 2014-07-11 2021-07-21 美商基利科學股份有限公司 用於治療ＨＩＶ之ｔｏｌｌ樣受體調節劑
SG11201701957XA (en) 2014-09-15 2017-04-27 Univ California Nucleotide analogs
MA42818A (fr) 2015-09-15 2018-07-25 Gilead Sciences Inc Modulateurs de récepteurs de type toll pour le traitement du vih
EP3350191B9 (de) 2015-09-15 2021-12-22 The Regents of the University of California Nukleotidanaloga
EP3372227A1 (de) 2017-03-06 2018-09-12 MH10 Spolka z ograniczona odpowiedzialnoscia Tablettenformulierung von adefovir dipivoxil
US11970482B2 (en) 2018-01-09 2024-04-30 Ligand Pharmaceuticals Inc. Acetal compounds and therapeutic uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1523865A (en) * 1974-09-02 1978-09-06 Wellcome Found Purine compunds and salts thereof
JPS52105195A (en) * 1976-03-01 1977-09-03 Wellcome Found Substituted purine
US4230708A (en) * 1977-10-20 1980-10-28 Stichting Rega V.Z.W. Therapeutic application of (S) -or (RS)-9-(2, 3-dihydroxypropyl) adenine for use as antiviral agents
CS233665B1 (en) * 1983-01-06 1985-03-14 Antonin Holy Processing of isomere o-phosphonylmethylderivative of anantiomere racemic vicinal diene
CS238038B1 (en) * 1983-10-07 1985-11-13 Antonin Holy Medical drug with antivirus effect

Also Published As

Publication number Publication date
EP0205826B1 (de) 1992-03-18
AU5646886A (en) 1986-10-30
EP0205826A2 (de) 1986-12-30
NZ215939A (en) 1988-09-29
ATE73663T1 (de) 1992-04-15
DK167342B1 (da) 1993-10-18
HK217296A (en) 1996-12-27
GR861089B (en) 1986-08-26
DK184186A (da) 1986-10-26
US4724233A (en) 1988-02-09
JPH0692307B2 (ja) 1994-11-16
DK184186D0 (da) 1986-04-22
EG18436A (en) 1993-02-28
JPS61275218A (ja) 1986-12-05
PT82457A (en) 1986-05-01
ZA863133B (en) 1987-02-25
IL78553A (en) 1989-09-28
AU586860B2 (en) 1989-07-27
PH23112A (en) 1989-04-19
IL78553A0 (en) 1986-08-31
EP0205826A3 (en) 1989-05-10
DE3684363D1 (de) 1992-04-23
PT82457B (pt) 1988-03-03
CA1272956A (en) 1990-08-21

Similar Documents

Publication Publication Date Title
CS263952B1 (en) Remedy with antiviral effect
De Clercq Vaccinia virus inhibitors as a paradigm for the chemotherapy of poxvirus infections
De Clercq S-Adenosylhomocysteine hydrolase inhibitors as broad-spectrum antiviral agents
Clercq et al. A novel selective broad-spectrum anti-DNA virus agent
US5321030A (en) Creatine analogs having antiviral activity
De Clercq et al. In vitro susceptibility of varicella-zoster virus to E-5-(2-bromovinyl)-2'-deoxyuridine and related compounds
De Clercq Broad-spectrum anti-DNA virus and anti-retrovirus activity of phosphonylmethoxyalkylpurines and-pyrimidines
Zakirova et al. Phosphoramidate derivatives of acyclovir: Synthesis and antiviral activity in HIV-1 and HSV-1 models in vitro
De Clercq et al. Selective in vitro and in vivo activities of 5-(2-haloalkyl) pyrimidine nucleoside analogs, particularly 5-(2-chloroethyl)-2'-deoxyuridine, against herpes simplex virus
CA2222154A1 (en) Acyclovir derivatives for topical use
De Clercq The antiviral spectrum of (E)-5-(2-bromovinyl)-2′-deoxyuridine
KEATING Antiviral agents
AU623341B2 (en) Antiviral therapy for hepatitis b
JP4545434B2 (ja) 抗ウイルス活性を有する６−‘２−（ホスホノメトキシ）アルコキシピリミジン誘導体
EP0294443B1 (de) Verwendung von nukleosiden zur herstellung eines medikamentes zur behandlung von krankheiten, die durch einen retrovirus oder den hepatitis-b-virus verursacht werden
JPH0618786B2 (ja) 医薬組成物
Machida et al. In vitro antiherpesviral activity of 5-alkyl derivatives of 1-β-d-arabinofuranosyluracil
JPS59186985A (ja) ジメチルアミノメチレン化された抗ヘルペス化合物
Wingard et al. Activity of trifluorothymidine against cytomegalovirus
JPH05507719A (ja) 薬学的治療
CS238038B1 (en) Medical drug with antivirus effect
CA1328865C (en) Composition and method for treating hepatitis virus infections using 1-(2'-deoxy-2'-fluoro-beta-d-arabino- furanosyl)-5-ethyluracil
Ayisi et al. Combination chemotherapy: interaction of 5-methoxymethyldeoxyuridine with trifluorothymidine, phosphonoformate and acycloguanosine against herpes simplex viruses
Barnard et al. Acyclic phosphonomethylether nucleoside inhibitors of respiratory viruses
Park et al. Efficacy of (E)-5-(2-bromovinyl)-2′-deoxyuridine in the treatment of experimental herpes simplex virus encephalitis in mice

Legal Events

Date Code Title Description
MK4A Patent expired

Effective date: 20000425